EL7.AI
StocksMediumUpdated×2•Originally published 4 September 2026•Updated 4 September 2026•
2 min read

Lucas GC Closes at $3.94 After 7.73% Drop; One-Month Slide Reaches 97.6%

Key Facts

1LGCL closed the September 3, 2026 session at $3.94, down 7.73%, after trading between $3.65 and $4.17.
2The adjusted decline was about 97.6%, from $162.50 on August 4, 2026 to $3.94 on September 3, 2026; the largest daily drop in the period was 82.86% on August 18.
3The 125-to-1 share consolidation became effective on September 1, 2026.
4The at-the-market program filed on August 7, 2026 permits sales of up to $25 million, but the prospectus does not establish that any issuance occurred.

Lucas GC shares, listed on Nasdaq under ticker LGCL, closed the September 3, 2026 session at $3.94, down 7.73%. The stock traded between $3.65 and $4.17 during the session.

The steep decline unfolded over a month, not one session. The consolidation-adjusted close fell from $162.50 on August 4, 2026 to $3.94 on September 3, 2026, a drop of about 97.6%. The largest displayed daily decline during that period was 82.86% on August 18, not 98%.

Lucas GC's 125-to-1 share consolidation became effective on September 1, 2026, and consolidation-adjusted trading began at the market open that day, according to the company announcement and a Nasdaq notice.

The transaction converted every 125 old shares into one new share, reducing the share count and raising the per-share reference price by the same factor before market movements. The company said proportional ownership would not change and fractional entitlements would be rounded up to the nearest whole share. Comparisons across the transaction must therefore use adjusted prices.

In a separate financing development, Lucas GC filed an August 7, 2026 prospectus supplement for an at-the-market share-sale program of up to $25 million through Pacific Century Securities. Sales, if any, may occur at market prices and at different times.

The prospectus does not establish that any shares were actually sold under the program. It says the agent need not sell a specified number or amount, the number of shares and proceeds are uncertain, and the company may sell none. Actual dilution cannot therefore be quantified, nor can the price decline be attributed to program issuance from this filing alone; subsequent disclosures would provide the relevant evidence of execution.